Q32 Bio (QTTB) Operating Income Growth (5y) (2022 - 2026)

Q32 Bio (QTTB) Operating Income Growth (5y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,839.48 Bn 65,839.20 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,015.37 Bn 1,015.37 Bn -
4 BeOne Medicines 471.39 Bn 466.59 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.52 Bn 115.28 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.33 Bn 61.58 Bn 3.31 Bn
7 Belite Bio 62.74 Bn 62.74 Bn -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn
10 Q32 Bio 215.80 Mn 165.05 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -47.37%
Dec 31, 2025 28.76%
Sep 30, 2025 23.15%
Jun 30, 2025 23.80%
Mar 31, 2025 19.64%
Dec 31, 2024 10.69%
Sep 30, 2024 9.67%
Jun 30, 2024 8.52%
Mar 31, 2024 9.99%
Dec 31, 2023 -5.05%
Sep 30, 2023 12.99%
Jun 30, 2023 11.53%
Mar 31, 2023 7.17%
Dec 31, 2022 -22.98%
Sep 30, 2022 -37.59%
Jun 30, 2022 -36.20%
Mar 31, 2022 -51.64%